Elutia Inc. is a commercial-stage company developing proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. Its cardiovascular biomatrix portfolio spans pericardial closure, intracardiac tissue repair, and vascular reconstruction. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. Its cardiovascular products are specifically designed to provide immediate structural support while promoting tissue regeneration, cellular infiltration, and natural integration over time. It is focused on developing NXT-41x, an antibiotic-eluting biomatrix designed to address post-operative infection. The NXT-41x product is designed to provide soft-tissue reinforcement while locally delivering antibiotics locally to inhibit bacterial colonization at the surgical site.
Back to dashboard
Company Information
About this company
Key people
Kevin L. Rakin
Lead Independent Chairman of the Board
C. Randal Mills
President, Chief Executive Officer, Director
Matthew B. Ferguson
Chief Financial Officer
Michelle LeRoux Williams
Chief Scientific Officer
David Colpman
Independent Director
Brigid A. Makes
Independent Director
Guido J. Neels
Independent Director
Click to see more
Key facts
- Shares in issue44.29m
- EPICELUT
- ISINUS05479K1060
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$37.65m
- Employees25
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.